EAEU Association of Pharmaceutical Manufacturers is working on the National Drug Policy specifically aimed at developing the domestic manufacturing. “Russia is rich not only in cardboard, and the development of manufacturing industry does not mean developing only the packaging,” said Dmitry Chagin, Chairman of EAEU Association of Pharmaceutical Manufacturers. In terms of drug provision, the priority of national policy should be the improvement of competencies in the area of full-cycle manufacturing localization, ranging from production of substances to manufacturing of finished dosage forms. “Right now, this is the principal goal of our organization,” said Dmitry Chagin.
For companies, this approach opens the prospects not only on the domestic market but also in terms of export potential.
“We need to clearly understand that only the competencies in the area of chemical and biological synthesis, and the development of substance manufacturing form foundation for the growth of exports. Those, who understand the technology and really have special competencies for the full-cycle manufacturing, are welcome participants for virtually all emerging markets,” said Zakhar Golant, Chairman of the Board at the Union of Pharmaceutical and Biomedical Clusters, a non-profit partnership.